Am J Surg

1. DURDEN JA, Tevis S
   Narrowing the gap: addressing sexual and gender minority-specific concerns throughout the breast cancer continuum.
   Am J Surg. 2026 May 2:117010. doi: 10.1016/j.amjsurg.2026.117010.
   

   >> Share

   
   

   
   Am J Surg Pathol

2. HASHMI AA, D'Alfonso TM, Brogi E, El-Tamer M, et al
   Occult Breast Carcinoma: Pathologic Features of an Uncommon Clinical Presentation in a Large Cohort.
   Am J Surg Pathol. 2026;50:687-694.
   

   >> Share

   
   
3. KARADAL-FERRENA B, Solomon JP, Lindeman N, Hoda SA, et al
   Clinicopathological and Molecular Features of Glycogen-Rich Breast Carcinoma.
   Am J Surg Pathol. 2026;50:599-607.
   

   >> Share

   
   

   
   Ann Surg

4. SAUCKE MC, Jacobson N, Chow S, McKinney G, et al
   Defer, Share, or Drive the Decision: Empowering Patients With Varied Preferences to Engage in Decision-making (an Analysis From Alliance A231701CD).
   Ann Surg. 2026;283:986-992.
   

   >> Share

   
   
5. LATTIMORE CM, Johnson HM, Kuerer HM, Caudle AS, et al
   Clipped Node Pathology as a Guide for Limited Axillary Surgery in Occult Breast Cancer.
   Ann Surg. 2026 May 15. doi: 10.1097/SLA.0000000000007093.
   

   >> Share

   
   

   
   Ann Surg Oncol

6. HAGER MG, Hoskin TL, Ruddy KJ, Boughey JC, et al
   Utility of 21-Gene Recurrence Score in Male Breast Cancer.
   Ann Surg Oncol. 2026 May 11. doi: 10.1245/s10434-026-19779.
   

   >> Share

   
   
7. RODRIGUEZ L, Wu R, Kassi A, Ishikawa T, et al
   ASO Visual Abstract: High PARP7 Expression is Associated with Higher Estrogen Response and Immune Suppression but Less Cell Proliferation and Better Survival in Breast Cancer.
   Ann Surg Oncol. 2026 May 11. doi: 10.1245/s10434-026-19789.
   

   >> Share

   
   
8. WANIS KN, Krasniqi R, Sun SX, Resetkova E, et al
   Sentinel Lymph Node Positivity and Utility of Frozen Section Diagnosis following Neoadjuvant Therapy in Patients with Clinically Node-Negative, Hormone Receptor-Positive, HER2-Negative Breast Cancer.
   Ann Surg Oncol. 2026 May 14. doi: 10.1245/s10434-026-19783.
   

   >> Share

   
   

   
   BMC Cancer

9. IHLAMUR M, Demi?rci?oglu A, Zorba AP, Abamor ES, et al
   Evaluating immunoreactivity of hybridoma-derived antibody mixtures generated against AU-565 cell line for diagnosis and immunotherapy of breast cancer.
   BMC Cancer. 2026 May 9. doi: 10.1186/s12885-026-16143.
   

   >> Share

   
   
10. TEPETAM H, Varan MP, Alomari O, Yildirim S, et al
    Cardiotoxicity perspective on the concurrent use of anti-HER2 agents and hypofractionated versus conventional fractionated locoregional radiotherapy in breast cancer.
    BMC Cancer. 2026 May 11. doi: 10.1186/s12885-026-16160.
    

    >> Share

    
    
11. SCHIZA A, Digkas E, Papadopoulos F, Skalkidou A, et al
    Endocrine therapy and COVID-19 outcomes in women with breast cancer: a nationwide register- based matched cohort study.
    BMC Cancer. 2026;26:598.
    

    >> Share

    
    
12. SETIAWAN G, Azhar Y, Abdurahman M, Soemitro MP, et al
    De-escalation of chemotherapy in HER2-positive breast cancer management: a systematic review and meta-analysis.
    BMC Cancer. 2026 May 14. doi: 10.1186/s12885-026-16149.
    

    >> Share

    
    
13. XIAO WT, He JY, Yang D, Xun Y, et al
    Construction of a novel signature based on CRISPR-Cas9 screening for prognostic prediction in breast cancer.
    BMC Cancer. 2026 May 14. doi: 10.1186/s12885-026-16167.
    

    >> Share

    
    

    
    Breast Cancer

14. YANG Q, Tang H, Fan Y, Liu B, et al
    Investigating the shared genetic architecture and causality of breast cancer and thyroid cancer: genome-wide cross trait analysis and bi-directional Mendelian randomization study.
    Breast Cancer. 2026 May 14. doi: 10.1007/s12282-026-01861.
    

    >> Share

    
    
15. KANO M, Taruno K, Inuzuka M, Makino R, et al
    Prevalence and clinical significance of germline pathogenic variants identified by multigene panel testing in high-risk Japanese patients with breast cancer.
    Breast Cancer. 2026 May 13. doi: 10.1007/s12282-026-01863.
    

    >> Share

    
    

    
    Breast Cancer (Auckl)

16. 
    Corrigendum to "Perceptions of Breast Cancer: A Cross-Sectional Study Using the Breast Cancer Perception Scale (BPS)".
    Breast Cancer (Auckl). 2026;20:11782234261449907.
    

    >> Share

    
    

    
    Breast Cancer (Dove Med Press)

17. ZHOU S, Yao R, Zhang M, Jiang M, et al
    Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study.
    Breast Cancer (Dove Med Press). 2026;18:589939.
    

    >> Share

    
    
18. KUSUMAHSTUTI KP, Holik HA, Bashari MH, Achmad A, et al
    ADPB Sensitivity in Breast Cancer is Correlated with LAT1 Expression: An in vitro Study of a Novel Theranostic Candidate.
    Breast Cancer (Dove Med Press). 2026;18:564513.
    

    >> Share

    
    
19. ABBASPOUR M, Esmaeil N, Akbari V, Ghoreishi M, et al
    Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review.
    Breast Cancer (Dove Med Press). 2026;18:588323.
    

    >> Share

    
    

    
    Breast Cancer Res

20. CHENG C, Yuan F, Li J, Fan Y, et al
    High-fat diet reshapes microbial interactions to promote breast cancer stemness via Streptococcus mutans-induced leucine accumulation.
    Breast Cancer Res. 2026 May 11. doi: 10.1186/s13058-026-02297.
    

    >> Share

    
    
21. MARTINEZ-ILLESCAS NG, Martin-Zapater E, Quezada-Gutierrez C, Yebenes L, et al
    Tumor ecology and the paradox of clean margins in multicentric breast cancer: an exploratory organoid-based functional study.
    Breast Cancer Res. 2026 May 9. doi: 10.1186/s13058-026-02301.
    

    >> Share

    
    
22. FISCHER-CARLES A, Fiorin A, Lopez Pablo C, Reverte L, et al
    Leveraging immune and clinicopathological profiles with machine learning to predict axillary lymph node metastasis in breast cancer patients.
    Breast Cancer Res. 2026 May 8. doi: 10.1186/s13058-026-02294.
    

    >> Share

    
    
23. HAZRA A, Berdan E, Walsh T, Humble S, et al
    Transcriptome predictors of second breast events in ductal carcinoma in situ: a case?control study including Black and White women.
    Breast Cancer Res. 2026;28:86.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

24. LIU Q, Wang R, Jiang S, Yuan J, et al
    Comparative efficacy of prevention strategies for oral mucositis in breast cancer patients: a network meta-analysis.
    Breast Cancer Res Treat. 2026;217:31.
    

    >> Share

    
    
25. FA'AK F, Haan J, Chmielewski-Stivers N, Menicucci A, et al
    Whole transcriptome analysis reveals MammaPrint and BluePrint-associated gene expression patterns with early lymph node metastasis in early-stage breast cancer.
    Breast Cancer Res Treat. 2026;217:30.
    

    >> Share

    
    
26. KONDO S, Kida K, Suzuki M, Kajiura Y, et al
    Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery.
    Breast Cancer Res Treat. 2026;217:35.
    

    >> Share

    
    
27. SLOTMAN E, de Munck L, Jager A, Honkoop AH, et al
    Characteristics, treatment and survival in de novo and metachronous metastatic breast cancer: a nationwide comparative analysis.
    Breast Cancer Res Treat. 2026;217:33.
    

    >> Share

    
    
28. OLSSON M, Janeva S, Martikainen J, Tzikas AK, et al
    Retrospective study of comparable survival after neoadjuvant versus adjuvant chemotherapy in cT1-2N0M0 triple-negative breast cancer.
    Breast Cancer Res Treat. 2026;217:34.
    

    >> Share

    
    
29. JIN Y, Li H, Yang Z, Luo S, et al
    Exploring the potential of postmastectomy radiotherapy in cN + and ypN0 breast cancer patients following neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2026;217:32.
    

    >> Share

    
    

    
    Cancer

30. FENG X, Zhang Y, Gao A, Lu Y, et al
    Breast cancer trends in China and its comparative analysis with group of 20 countries: Projections for 2022-2040.
    Cancer. 2026;132:e70379.
    

    >> Share

    
    
31. NICOLO E, Bertucci F, Boussen H, Curigliano G, et al
    Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025.
    Cancer. 2026;132:e70447.
    

    >> Share

    
    

    
    Cancer Chemother Pharmacol

32. VERHAGEN NE, Touw DCW, van den Heuvel JJMW, van den Broek PH, et al
    Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia.
    Cancer Chemother Pharmacol. 2026;96:47.
    

    >> Share

    
    

    
    Cancer Res

33. YOO JY, Akter S, Zuo Q, Rilloraza M, et al
    In Silico Reconstruction of Primary and Metastatic Tumor Architecture Using Geographic Information System-Augmented Spatial Transcriptomics.
    Cancer Res. 2026;86:2555-2568.
    

    >> Share

    
    
34. FLAHERTY RL, Hughes F, Sflomos G, Ronchi C, et al
    LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma.
    Cancer Res. 2026;86:2487-2507.
    

    >> Share

    
    

    
    Carcinogenesis

35. WANG Y, Wu Y, Zheng S, Yan X, et al
    Stromal NNMT overexpression as an independent prognostic biomarker in lung adenocarcinoma and breast carcinoma.
    Carcinogenesis. 2026;47:bgag020.
    

    >> Share

    
    

    
    Cell

36. SHULMAN ED, Campagnolo EM, Lodha R, Chung Y, et al
    AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology.
    Cell. 2026 May 8:S0092-8674(26)00458-7. doi: 10.1016/j.cell.2026.
    

    >> Share

    
    

    
    Clin Breast Cancer

37. BJORNSTROM MS, Niinikoski L, Stahls A, Mattson J, et al
    Impact of Preoperative MRI on Surgical and Long-term Outcome in Patients With Invasive Lobular Carcinoma (ILC): A Retrospective Cohort Study.
    Clin Breast Cancer. 2026;26:11-18.
    

    >> Share

    
    
38. ZHANG R, Qiu X, Kong X, Wong PP, et al
    Global Burdens and Trends of Breast Cancer Attributable to Dietary and Metabolic Risks: A 30-Year Analysis With Projections to 2050, Including Males and Females.
    Clin Breast Cancer. 2026 Apr 16:S1526-8209(26)00063.
    

    >> Share

    
    
39. AMORIM AG, Mattar A, Antonini M, Cabrera CRM, et al
    Cost-Minimization Analysis of Vacuum-Assisted Biopsy Versus Surgical Biopsy for the Diagnosis of Suspicious Breast Lesions in the Brazilian Public Health System.
    Clin Breast Cancer. 2026;26:130-139.
    

    >> Share

    
    
40. ARAEN T, Arruda R, Bernstein MH, Baird GL, et al
    What Will Patients Find When They Search Online for AI and Mammography? An Examination of Readability and Understandability Metrics in Online Patient Education Materials.
    Clin Breast Cancer. 2026;26:36-45.
    

    >> Share

    
    
41. KNOEDLER SA, Wirtz JM, Sofo G, Yuste M, et al
    Venous Thromboembolism After Pedicled TRAM Versus Free Flap Breast Reconstruction: A Propensity-Matched Analysis.
    Clin Breast Cancer. 2026;26:19-28.
    

    >> Share

    
    
42. NEGREANU RA, Verga N, Gainariu E
    Taxane-Induced Peripheral Neuropathy-Driven Treatment Modification and Pathologic Complete Response After Neoadjuvant TCHP in HER2-Positive Breast Cancer: A Retrospective Cohort Study.
    Clin Breast Cancer. 2026;26:44-51.
    

    >> Share

    
    
43. YANG W, Zhang Y, Chen M, Yang Y, et al
    The Mediating Role of Serum Phosphate in the BMI-Breast Cancer Association: A Prospective Study from the UK Biobank.
    Clin Breast Cancer. 2026;26:52-61.
    

    >> Share

    
    
44. KIMMICK G, Pilehvari A, You W, Bonilla G, et al
    Clinical and Demographic Characteristics of Patients With Long-Term Disease Control With First-Line Endocrine Therapy Alone for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer.
    Clin Breast Cancer. 2026;26:62-70.
    

    >> Share

    
    
45. DU J, Duan C, Zhang J, Zhou Y, et al
    Impact of Typical Somatic Gene Mutation Characteristics on Homologous Recombination Deficiency in Breast Cancer.
    Clin Breast Cancer. 2026 Apr 21:S1526-8209(26)00068.
    

    >> Share

    
    

    
    Clin Cancer Res

46. STRAWSER CH, Chakraborty B, Michaud D, Chang CY, et al
    Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy.
    Clin Cancer Res. 2026 May 13. doi: 10.1158/1078-0432.CCR-25-0946.
    

    >> Share

    
    

    
    Gene

47. HAN MI, Atalay P, Satir-Basaran G
    The VEGF/VEGFR axis in triple-negative breast cancer: a comprehensive review of therapeutic strategies.
    Gene. 2026 May 6:150201. doi: 10.1016/j.gene.2026.150201.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

48. OKONOGI N, Karasawa K, Murata K, Omatsu T, et al
    Carbon-Ion Radiation Therapy as Nonsurgical Treatment for Early-Stage Breast Cancer: 5-Year Results From the Phase 2 Part of the First Prospective Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2026;124:971-976.
    

    >> Share

    
    

    
    J Biol Chem

49. HUMPHRIES BA, Wang Z, Yang C
    Methylation Marks Breast Cancer Metastasis: The Roles of m(6)A-Modified miRNAs and lncRNAs.
    J Biol Chem. 2026 May 6:113127. doi: 10.1016/j.jbc.2026.113127.
    

    >> Share

    
    

    
    J Clin Oncol

50. VICINI FA, Winter K, Freedman GM, Arthur DW, et al
    Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial.
    J Clin Oncol. 2026 May 11:JCO2502465. doi: 10.1200/JCO-25-02465.
    

    >> Share

    
    

    
    J Nucl Med

51. DUIJX LEHW, Lenaerts M, Smidt ML, Vaz SC, et al
    Diagnostic Performance of FAPI PET in Patients with Breast Cancer: A Systematic Review.
    J Nucl Med. 2026 May 14:jnumed.126.272191. doi: 10.2967/jnumed.126.272191.
    

    >> Share

    
    

    
    J Surg Oncol

52. LEE SH, Kohler A, Tingen J, King CA, et al
    Cost-Utility Analysis of Indocyanine Green Versus Methylene Blue for Sentinel Lymph Node Biopsy in Breast Cancer.
    J Surg Oncol. 2026 May 10. doi: 10.1002/jso.70278.
    

    >> Share

    
    
53. BAUMRUCKER CC, Harris N, Aiello P, Whiting J, et al
    Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer.
    J Surg Oncol. 2026 May 13. doi: 10.1002/jso.70287.
    

    >> Share

    
    

    
    Lancet Oncol

54. NAOUM GE
    Reshaping breast cancer radiotherapy after FAST-Forward.
    Lancet Oncol. 2026 May 14:S1470-2045(26)00192.
    

    >> Share

    
    

    
    Mol Ther Oncol

55. DAQUINAG AC, Ghosh SC, AghaAmiri S, Farmer SM, et al
    Fibulin-4 expressed in metastatic breast cancer is a target of peptide-based imaging probes and experimental therapeutics.
    Mol Ther Oncol. 2026;34:201207.
    

    >> Share

    
    

    
    Nature

56. CASSANDRAS M, Sanchez X, Hsu L, Huang Y, et al
    A glucocorticoid-FAS axis controls immune evasion during metastatic seeding.
    Nature. 2026;653:567-575.
    

    >> Share

    
    
57. YAN Y, Lin Y, Kumar T, Bai S, et al
    Ecotypes of triple-negative breast cancer in response to chemotherapy.
    Nature. 2026 May 13. doi: 10.1038/s41586-026-10469.
    

    >> Share

    
    

    
    NPJ Breast Cancer

58. SCHLAM I, Tang G, AbdulJabbar K, Yan H, et al
    AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.
    NPJ Breast Cancer. 2026 May 14. doi: 10.1038/s41523-026-00961.
    

    >> Share

    
    
59. DI COSIMO S, Apolone G
    Beyond timing, toward precision: insights from CDK4/6 inhibitor trials in metastatic breast cancer.
    NPJ Breast Cancer. 2026 May 12. doi: 10.1038/s41523-026-00958.
    

    >> Share

    
    
60. VAN DEN ENDE NS, Smid M, Martens JWM, Debets R, et al
    Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions.
    NPJ Breast Cancer. 2026 May 13. doi: 10.1038/s41523-026-00964.
    

    >> Share

    
    
61. ABDOU Y, Rozenblit M, Trapani D, Zerdes I, et al
    Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2).
    NPJ Breast Cancer. 2026;12:69.
    

    >> Share

    
    
62. KUBECZKO M, Polakiewicz-Gilowska A, d'Amico A, Chrabanski O, et al
    Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer.
    NPJ Breast Cancer. 2026 May 11. doi: 10.1038/s41523-026-00962.
    

    >> Share

    
    
63. TERAO M, Kumamaru H, Kinukawa N, Hanamura T, et al
    Risk factors and metastatic sites in HER2-positive breast cancer with pathological complete response.
    NPJ Breast Cancer. 2026 May 9. doi: 10.1038/s41523-026-00959.
    

    >> Share

    
    

    
    Oncogene

64. GHERGHELAS AM, Toseland CP
    ESR1 fusion proteins in breast cancer: distinguishing oncogenic drivers from passenger events.
    Oncogene. 2026 May 14. doi: 10.1038/s41388-026-03813.
    

    >> Share

    
    

    
    PLoS Comput Biol

65. LEYVA A, Akbar AR, Niazi MKK
    Predicting protein cascade expression from H&E images.
    PLoS Comput Biol. 2026;22:e1014262.
    

    >> Share

    
    

    
    PLoS Genet

66. LI Q, Wang D, Zhang Z, Perera D, et al
    Tissue-specific transfer learning improves functional variant and therapeutic target discoveries in breast and prostate cancer.
    PLoS Genet. 2026;22:e1012145.
    

    >> Share

    
    

    
    PLoS One

67. JAMADAR IS, Kumar K, Khan A, Khan SA, et al
    Optimizing breast cancer treatment strategies through fractional-order dynamics: A computational modeling approach.
    PLoS One. 2026;21:e0347160.
    

    >> Share

    
    
68. CHAUVIN P, Huet T, Gligorov J, Sargent C, et al
    Social disparities in the frequency and severity of triple-negative breast cancer at diagnosis in a university hospital in Paris, France: confronting race and ethnic blindness.
    PLoS One. 2026;21:e0349041.
    

    >> Share

    
    
69. FUENTES-EXPOSITO MA, Frid S, Munoz-Mateu M, Siso-Almirall A, et al
    Feasibility of the Xemio app for breast cancer survivors in a clinical setting: Adherence, acceptance, and side effect monitoring (CTCAE vs. QoL).
    PLoS One. 2026;21:e0342702.
    

    >> Share

    
    
70. AQUINO LCM, Andrade EIS, Nunes LMF, Santos EM, et al
    Analysis of tumor-infiltrating lymphocytes as prognostic factor in triple-negative breast cancer: A protocol of systematic review and meta-analysis.
    PLoS One. 2026;21:e0342085.
    

    >> Share

    
    
71. LI Y, Chen Y, Xu C, Zhan W, et al
    An exploratory dosimetric and treatment-time analysis of tangent-arc and continuous semi-arc VMAT in deep inspiration breath-hold radiotherapy for stage I left-sided breast cancer.
    PLoS One. 2026;21:e0348570.
    

    >> Share

    
    

    
    Radiologia (Engl Ed)

72. GRANA-LOPEZ L, Abelairas-Lopez L, Correa-Lugilde N, Fernandez-Sobredo I, et al
    Imaging findings after cryoablation of breast cancer.
    Radiologia (Engl Ed). 2026;68:501688.
    

    >> Share

    
    
73. ALCANTARA R, Azcona J, Vall E, Vila-Trias E, et al
    Applying the BI-RADS(R) lexicon to contrast-enhanced mammography: Establishing a framework for report standardisation.
    Radiologia (Engl Ed). 2026;68:101641.
    

    >> Share

    
    

    
    Radiother Oncol

74. HOGSBJERG KW, Thomsen MS, Maae E, Mjaaland I, et al
    Validation of the ESTRO target volume consensus guideline for early-stage breast cancer in the DBCG Skagen Trial 1.
    Radiother Oncol. 2026 May 13:111594. doi: 10.1016/j.radonc.2026.111594.
    

    >> Share

    
    
75. MONTANARI J, Vinasco-Sandoval T, Lemaitre G, Vogin G, et al
    Non-coding (nc) RNAs and breast cancer treatment related sequelae: Current evidence and perspectives.
    Radiother Oncol. 2026 May 10:111570. doi: 10.1016/j.radonc.2026.111570.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share